Skip to main content
SpringerLink
Log in

Safety Profile of Desmopressin Tablet for Enuresis in a Prospective Study

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

This pre-specified sub-study of the desmopressin response in primary nocturnal enuresis study (DRIP study) evaluates the safety profile of the oral desmopressin tablet in children with primary nocturnal enuresis. Endpoints are adverse events and change in body mass index.

Methods

The DRIP study was an open-label, intention-to-treat, phase IV, multi-national study. Overall, 936 patients were screened and 744 children aged 5–15 years with previously untreated primary nocturnal enuresis were eligible to receive the study medication desmopressin once daily as an oral tablet formulation. At each visit, adverse events were questioned and observed signs or symptoms were recorded.

Results

Overall, 222 (30%) patients experienced 404 treatment-emergent adverse events. The proportion of patients experiencing treatment-emergent adverse events was similar regardless of patient gender or age. Most treatment-emergent adverse events were experienced in three system organ classes: gastrointestinal disorders; infections and infestations; and respiratory, thoracic and mediastinal disorders and were considered unrelated to the study drug. There was a slight increase in body mass index from screening levels during the study, however, clinically not significant.

Conclusion

Desmopressin tablet treatment is well tolerated in children with primary nocturnal enuresis, regardless of patient gender or age.

Funding

The desmopressin response in primary nocturnal enuresis study (DRIP- study) was funded by Ferring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hjalmas K, Arnold T, Bower W, et al. Nocturnal enuresis: an international evidence based management strategy. J Urol. 2004;171(6 Pt 2):2545–61.

    Article  CAS  PubMed  Google Scholar 

  2. Neveus T, Eggert P, Evans J, et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children’s Continence Society. J Urol. 2010;183(2):441–7.

    Article  PubMed  Google Scholar 

  3. Glazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2005;2:CD002911.

    PubMed  Google Scholar 

  4. Neveus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol. 2006;176(1):314–24.

    Article  PubMed  Google Scholar 

  5. Vande Walle J, Rittig S, Bauer S, et al. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012;171(6):971–83.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2002;3:CD002112.

    PubMed  Google Scholar 

  7. Djurhuus JC, Norgaard JP, Rittig S. Monosymptomatic bedwetting. Scand J Urol Nephrol Suppl. 1992;141:7–17 (discussion 8–9).

    CAS  PubMed  Google Scholar 

  8. Van de Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf Int J Med Toxicol Drug Exp. 2010;33(4):261–71.

    Article  Google Scholar 

  9. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol. 2007;178(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  10. VandeWalle J, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007;2(3):232–8.

    Article  CAS  Google Scholar 

  11. Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr. 1996;155(11):959–62.

    Article  CAS  PubMed  Google Scholar 

  12. Lucchini B, Simonetti GD, Ceschi A, et al. Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review. J Pediatr Urol. 2013;9(6 Pt B):1049–53.

    Article  PubMed  Google Scholar 

  13. Dehoorne JL, Raes AM, van Laecke E, Hoebeke P, Vande Walle JG. Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. J Urol. 2006;176(2):754–7 (discussion 7–8).

    Article  CAS  PubMed  Google Scholar 

  14. De Guchtenaere A, Raes A, Vande Walle C, et al. Evidence of partial anti-enuretic response related to poor pharmacodynamic effects of desmopressin nasal spray. J Urol. 2009;181(1):302–9 (discussion 9).

    Article  PubMed  Google Scholar 

  15. Lottmann H, Baydala L, Eggert P, et al. Long-term desmopressin response in primary nocturnal enuresis: open-label, multinational study. Int J Clin Pract. 2009;63(1):35–45.

    Article  CAS  PubMed  Google Scholar 

  16. Van Herzeele C, Alova I, Evans J, et al. Poor compliance with primary nocturnal enuresis therapy may contribute to insufficient desmopressin response. J Urol. 2009;182(4 Suppl):2045–9.

    Article  PubMed  Google Scholar 

  17. Juul KV, Klein BM, Sandstrom R, Erichsen L, Norgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):F1116–22.

    Article  CAS  PubMed  Google Scholar 

  18. De Bruyne P, De Guchtenaere A, Van Herzeele C, et al. Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr. 2014;173(2):223–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The desmopressin response in primary nocturnal enuresis study (DRIP study) was funded by Ferring. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest

C. Van Herzeele, J. Evans and P. Eggert declare that they have no actual or potential conflict of interest. P. De Bruyne received an independent Grant for Strategic Basic Research of the Agency for Innovation by Science and Technology in Flanders (IWT). H. Lottmann is a lecturer and advisor for Ferring Pharmaceuticals. J. Norgaard is a full time employee of Ferring Pharmaceuticals. J. Vande Walle is a lecturer, investigator and advisor for Ferring Pharmaceuticals.

Compliance with ethics guidelines

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients before being included in the study.

Author information

Authors and Affiliations

  1. Department of Pediatric Nephrology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium

    Charlotte Van Herzeele, Pauline De Bruyne & Johan Vande Walle

  2. Children’s Renal and Urology Unit, Nottingham Children’s Hospital, Nottingham University Hospitals NHS Trust, Queens, Medical Centre Campus, Derby Road, Nottingham, NG7 2UH, UK

    Jonathan Evans

  3. Klinik f. Allgemeine Pädiatrie, UKSH, Campus Kiel, Schwanenweg 15, 24105, Kiel, Germany

    Paul Eggert

  4. Service de chirurgie viscérale pédiatrique, Hôpital Necker-Enfants Malades, 149, rue de Sèvres, 75015, Paris, France

    Henri Lottmann

  5. Ferring, Global Scientific affairs Urology Ferring International PharmaScience Centre, Kay Fiskers Plads 11, 2300, Copenhagen, Denmark

    Jens Peter Norgaard

Authors
  1. Charlotte Van Herzeele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pauline De Bruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Eggert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henri Lottmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jens Peter Norgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johan Vande Walle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charlotte Van Herzeele.

Additional information

Trial registration: Clinical Trials.gov Identifier: NCT00245479.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 205 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Herzeele, C., De Bruyne, P., Evans, J. et al. Safety Profile of Desmopressin Tablet for Enuresis in a Prospective Study. Adv Ther 31, 1306–1316 (2014). https://doi.org/10.1007/s12325-014-0173-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-014-0173-1

Keywords

Search

Navigation